Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 April, 2018 08:24 IST
Cipla's arm receives final nod for generic Renvela tablets
Source: IRIS | 27 Oct, 2017, 10.00AM
Comments  |  Post Comment

Cipla's subsidiary, InvaGen Pharmaceuticals Inc., has received final approval for its Abbreviated New Drug Application (ANDA) for Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Genzyme’s Renvela Tablets, 800 mg.

Renvela Tablets had US sales of approximately USD 1.85 billion for the 12-month period ending August 2017, according to IMS Health. Sevelamer Carbonate Tablets, 800 mg is a AB-rated generic equivalent to the reference listed drug (RLD), Renvela Tablets, 800 mg of Genzyme Corporation and are indicated for the control of serum phosphorus in adults with chronic kidney disease (CKD) on dialysis.

Shares of the company gained Rs 10.1, or 1.65%, to trade at Rs 622.50. The total volume of shares traded was 130,385 at the BSE (9.48 a.m., Friday).



Cipla Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Welspun Corp bags contract to supply water pipes in MENA region - 20-Apr-2018 10:17
TVS Motor Company launches TVS XL100 Heavy Duty 'i-Touch Start' - 20-Apr-2018 10:14
Yes Bank receives RBI approval to open overseas offices - 20-Apr-2018 10:07
Glenmark Pharma gets final nod for Clobetasol Propionate solution - 20-Apr-2018 10:03
TCS Q4 earnings grow 5.7% sequentially to Rs 69.04 bn - 20-Apr-2018 10:00
Prism Cement is now Prism Johnson - 19-Apr-2018 15:51
NACL Ind enters into strategic alliance with BioWorks - 19-Apr-2018 15:25
Ramco Systems partners with L3 MAS - 19-Apr-2018 15:21
MCX inks pact with Northern India Textiles Mills' Association - 19-Apr-2018 15:16
BP and Reliance sanction second phase of integrated KG D6 development - 19-Apr-2018 13:45
IndusInd Bank Q4 profit grows 27% to Rs 9.53 bn - 19-Apr-2018 13:40
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer